For licensed practitioners treating moderate-to-large body pockets, a CE-marked Aqualyx-style microgel is usually the more versatile, better-evidenced choice for UK practice. For small, well-defined submental fat deposits, prescription deoxycholic-acid formulations can deliver faster, more aggressive reduction — but they carry stricter prescribing requirements, a stronger inflammatory response, and more limited availability outside certain markets.
Two practical reasons drive that split:
- Regulatory and supply chain clarity: CE-marked Aqualyx has an established UK and EU distribution history through licensed pharmacy channels, giving practitioners a traceable, auditable supply route. Prescription deoxycholic-acid formulations require prescription-only handling and, depending on the market, specific manufacturer training before a clinic can legitimately source them.
- Mechanism and downtime trade-off: The microgel matrix in Aqualyx-style products slows the release of the active compound, producing a more gradual inflammatory response and typically less acute swelling. Prescription deoxycholic-acid formulations act faster but generate a sharper, more intense inflammatory phase — which matters enormously for patient scheduling and consent.
Warning: Never source fat-dissolving injectables from unlicensed or grey-market suppliers. Unverified products carry unknown formulation risks and expose both patient and practitioner to serious harm. Appropriate training and a valid prescribing framework are non-negotiable before offering any injectable adipocytolysis treatment.
Key takeaways
Aqualyx-style CE-marked microgel is the more versatile, better-evidenced choice for larger body pockets in UK practice, while prescription deoxycholic-acid formulations suit small, isolated submental deposits where faster reduction justifies a stronger inflammatory response.
| Point | Details |
|---|---|
| Match agent to area | Use CE-marked microgel for larger body pockets; reserve prescription deoxycholic-acid formulations for isolated submental fat. |
| Verify supply chain first | Source only from licensed pharmacies with batch numbers and authorised distributor letters before any order. |
| Communicate downtime honestly | Prescription formulations cause stronger swelling lasting 2–4 weeks; microgel reactions are milder and shorter. |
| Select patients carefully | Weight-stable patients with localised fat deposits and realistic expectations are the appropriate candidates. |
| Mirror Pharma supply | Mirror Pharma supplies Aqualyx fat dissolve vials to licensed practitioners through verified, traceable channels. |
How do Kybella and Aqualyx compare across key clinical dimensions?
The comparison below uses neutral category labels to reflect the class-level differences between CE-marked Aqualyx-style microgel and prescription deoxycholic-acid formulations. For qualified aesthetic professionals, these are the dimensions that actually drive clinical decision-making.
| Category | Aqualyx-style CE-marked microgel | Prescription deoxycholic-acid formulations |
|---|---|---|
| Active ingredient profile | Deoxycholic-acid derivative in buffered galactose/polymer microgel matrix | Purified synthetic deoxycholic acid in saline |
| Regulatory status | CE-marked medical device/product; licensed pharmacy supply in UK/EU | Prescription-only medicine in most markets; FDA-authorised for submental use in some countries |
| Typical treatment areas | Submental, jowls, abdomen, thighs, inner knees, flanks | Primarily submental; off-label use in other areas requires extra clinical caution |
| Injection technique | 25–27G needle or blunt cannula; fan or grid pattern | Fine 30G needle; precise submental grid technique |
| Session count and interval | Typically 2–8 sessions, spaced 4–6 weeks apart | Up to 6 sessions, spaced approximately 4 weeks apart |
| Common side effects | Swelling, bruising, tenderness, transient nodules | Pronounced swelling, erythema, numbness, higher nodularity risk |
| Training and supply channel | Manufacturer or academy training; authorised distributor/licensed pharmacy | Prescription-only supply; manufacturer training often mandatory |
| Cost shape | Lower per-vial cost; more sessions may be needed | Higher per-vial cost; potentially fewer sessions for submental work |
Top three actionable differentiators for decision-making:
- Match the agent to the area: Aqualyx-style microgel for larger or multiple body pockets; prescription deoxycholic-acid formulations for isolated, small submental deposits.
- Factor in downtime: prescription formulations produce stronger acute swelling, which affects patient scheduling and satisfaction if not communicated clearly.
- Confirm your supply chain before you prescribe or order: CE-marked products through authorised distributors reduce the regulatory and safety unknowns that come with unlicensed alternatives.
What does each formulation contain and how does it destroy fat?
Both agents work through adipocytolysis — the disruption of adipocyte cell membranes leading to fat-cell death and subsequent clearance via the lymphatic system. The formulation differences, however, produce meaningfully different clinical behaviour.
Aqualyx-style microgel
Aqualyx is a CE-marked injectable whose active compound is a deoxycholic-acid derivative suspended in a buffered galactose and polymer microgel matrix. The matrix is not cosmetic packaging — it slows the release of the active compound into surrounding tissue, which moderates the speed and intensity of the inflammatory response. The result is a more gradual breakdown of adipocytes over days rather than hours, with correspondingly milder acute swelling and a lower peak inflammatory load.
Prescription deoxycholic-acid formulations
Prescription deoxycholic-acid formulations use purified synthetic deoxycholic acid in a saline solution, typically at 10 mg/mL. Without a sustained-release matrix, the compound acts more immediately on adipocyte membranes, producing faster cell disruption. That speed is clinically useful for small, defined submental pockets where a practitioner wants a concentrated effect in a limited anatomical zone. The trade-off is a sharper inflammatory phase: more pronounced swelling, greater tenderness, and a higher likelihood of transient nodule formation compared with microgel-based products.
The shared mechanism pathway
Both agents follow the same fundamental pathway:
- Deoxycholic acid disrupts the phospholipid bilayer of adipocyte membranes.
- Cell contents are released, triggering a localised inflammatory response.
- Macrophages clear the cellular debris over several weeks.
- The lymphatic system removes the breakdown products, gradually reducing the treated fat pocket.
Mechanism note for practitioners: The formulation determines how fast that inflammatory cascade peaks, not whether it occurs. A slower peak (microgel) means more manageable downtime and less patient anxiety; a faster peak (saline-based prescription formulation) means quicker visible change but a more demanding recovery window. Plan your consent conversation accordingly.
What is the regulatory standing of each product?
Regulatory status is not a bureaucratic footnote — it determines whether you can legally source, prescribe, and administer a product, and whether your indemnity insurer will cover you if something goes wrong.
CE-marked Aqualyx-style products
CE-marked Aqualyx has an established supply history in the UK and EU through licensed pharmacy and authorised distributor channels. CE marking indicates conformity with applicable European product standards and provides a documented framework for traceability. Real-world clinic reporting supports that CE-marked Aqualyx has a long UK and EU supply history with documented safety protocols; supply-chain transparency and authorised pharmacy distribution reduce the unknowns associated with unlicensed products.
Prescription deoxycholic-acid formulations
In many markets, including the UK, deoxycholic-acid formulations for submental fat are classified as prescription-only medicines. That classification means a valid prescription from a qualified prescriber is required before supply, and the product must move through a licensed pharmacy. In some countries, the same class of product holds formal regulatory authorisation (for example, FDA authorisation in the United States for submental use). In the UK, practitioners should confirm the precise regulatory classification of any deoxycholic-acid product they intend to use and ensure their prescribing and supply arrangements are fully compliant.
Regulator warnings about unlicensed products
Regulator position: UK regulators and professional bodies have issued clear warnings about unlicensed or grey-market cosmetic injectables, including fat-dissolving products sold outside licensed pharmacy supply chains. Unknown formulation, absent quality controls, and no traceability are the core risks. Clinicians should prioritise regulated, traceable products where possible.
Pro Tip: Before ordering any fat-dissolving injectable, request the batch number, pharmacy invoice, and authorised distributor letter from your supplier. Cross-reference against MHRA notices on unlicensed medicines. If a supplier cannot provide this documentation, do not order.
Which technique and treatment areas suit each agent?
Technique is where the formulation differences become most practically visible. Getting the needle gauge, injection pattern, and depth wrong with either agent increases complication risk substantially.
Aqualyx-style microgel technique
Aqualyx-style microgel is typically injected with 25–27G needles or a blunt cannula, depending on the treatment area and practitioner preference. Blunt cannula is particularly useful for larger body areas such as the abdomen, thighs, and flanks, where it reduces the risk of inadvertent intravascular injection. The standard pattern is a fan or grid distribution at mid-subcutaneous depth, with microbolus volumes typically in the range of 0.2–0.5 mL per injection point. Multiple passes across a larger area allow even distribution of the microgel.
Prescription deoxycholic-acid formulation technique
Prescription deoxycholic-acid formulations are administered with fine 30G needles in a precise grid pattern, most commonly in the submental region. The grid spacing is typically around 1 cm between injection points, with small, consistent microbolus volumes to achieve an even distribution across the fat pad. Depth control is critical here: too superficial risks dermal necrosis; too deep risks muscle injection and potential marginal mandibular nerve injury.
Treatment area matching
- Submental (chin) fat: Both agents are used here. Prescription deoxycholic-acid formulations are the more studied option for isolated submental work; Aqualyx-style microgel is also used but tends to be preferred when the submental pocket is part of a broader lower-face and jowl treatment plan.
- Jowls and lower face: Aqualyx-style microgel, with careful technique and conservative volumes.
- Abdomen, flanks, thighs, inner knees: Aqualyx-style microgel is the standard choice for these larger body pockets; prescription deoxycholic-acid formulations in these areas are off-label and require additional clinical justification.
Area-matching principle: Use a CE-marked microgel for larger or multiple body pockets where gradual contouring and lower acute inflammation are priorities. Reserve prescription deoxycholic-acid formulations for small, well-defined submental deposits where speed of reduction and precision outweigh the stronger inflammatory response.
How many sessions are needed and when do results appear?
Setting realistic timelines is one of the most important parts of the consent process for injectable adipocytolysis. Patients who expect dramatic change after one session are the ones most likely to be dissatisfied, regardless of how technically sound the treatment was.
- Aqualyx-style microgel: Most patients require 2–8 sessions, spaced 4–6 weeks apart. The range is wide because it depends heavily on the volume of fat being treated, the anatomical area, and individual lymphatic clearance rates. Larger body pockets at the higher end; smaller, well-defined areas at the lower end.
- Prescription deoxycholic-acid formulations: Up to 6 sessions are typical for submental use, spaced approximately 4 weeks apart. The faster adipocyte disruption means some patients see earlier visible change, but the full assessment of results should still be made no sooner than 4–6 weeks after the final session.
- First visible change: With Aqualyx-style microgel, visible contouring changes typically emerge over several weeks as inflammation resolves and lymphatic clearance progresses. Prescription formulations can produce earlier visible reduction, but the pronounced swelling in the first 1–2 weeks can temporarily obscure the result.
- Factors that slow clearance: Poor lymphatic function, high BMI, sedentary lifestyle, and inadequate post-treatment care all extend the timeline. Post-procedure care including compression where appropriate, lymphatic drainage, and avoidance of heat and alcohol speeds recovery and reduces patient dissatisfaction, particularly after more inflammatory agents.
- Durability: Destroyed adipocytes do not regenerate. However, remaining fat cells in the treated area can still expand with significant weight gain. Practitioners should communicate this clearly: the result is durable provided weight remains stable, not unconditional.
What are the side effects and how should complications be managed?
Both agents share a predictable immediate reaction profile, but the intensity differs. For qualified aesthetic professionals, knowing the difference between expected reactions and warning signs is the foundation of safe practice.
Common immediate reactions
- Swelling (oedema): Expected with both agents. Typically resolves within 1–2 weeks for Aqualyx-style microgel; can be more pronounced and last 2–4 weeks with prescription deoxycholic-acid formulations.
- Bruising: Common at injection sites; usually resolves within 7–10 days.
- Tenderness and erythema: Predictable; managed with standard aftercare advice (cool compresses, avoiding heat and strenuous exercise for 48 hours).
- Numbness: More commonly reported with prescription deoxycholic-acid formulations in the submental area; usually transient.
Less common but important complications
- Nodules and prolonged induration: Can occur with either agent, more frequently with prescription formulations. Most resolve spontaneously over weeks; persistent nodules may require ultrasound assessment and, rarely, surgical drainage.
- Infection: Rare with sterile technique; treat promptly with appropriate antibiotics if suspected.
- Asymmetry: Usually technique-related; document pre-treatment asymmetry with photographs to distinguish pre-existing from treatment-related.
- Marginal mandibular nerve injury: A specific risk with submental injections if depth control is inadequate. Presents as unilateral smile asymmetry; most cases resolve within weeks to months but require urgent review and documentation.
Red-flag checklist for urgent review
- Increasing pain beyond 48 hours post-treatment
- Signs of skin necrosis (blanching, dusky discolouration, blistering)
- Fever or systemic signs of infection
- Sudden onset of facial asymmetry suggesting nerve involvement
- Firm, enlarging nodule not resolving after 6 weeks
Safety imperative: Injectable adipocytolysis must only be performed by practitioners with documented injection competency, emergency management training, and a clear escalation pathway. Informed consent must cover the full complication profile, including rare but serious events. Sterile technique is non-negotiable. Aqualyx has an established safety record in Europe but most complications reported in real-world series are technique- and sourcing-related, not inherent to the product itself.
Which patients are suitable candidates and what does the evidence show?
Injectable adipocytolysis is a contouring tool, not a weight-loss method. That distinction shapes every aspect of patient selection.
Evidence summary
Phase-3 randomised trials and follow-up studies for the deoxycholic-acid class demonstrate statistically significant submental fat reduction versus placebo, with some multi-year follow-up indicating durable improvement in responders. This is the strongest evidence base in the injectable adipocytolysis category. For Aqualyx-style products, the evidence base is predominantly observational and post-market: extensive real-world use across European clinics, but fewer randomised controlled trials. Reviews of injectable adipocytolysis approaches note heterogeneity in evidence and emphasise that direct head-to-head RCTs between different formulations are limited, so comparative claims should be framed cautiously.
Candidate checklist for licensed practitioners
- Weight stability: Patients should be at or near their target weight. Significant ongoing weight loss or gain makes results unpredictable and patient satisfaction difficult to achieve.
- BMI: Both agents are most effective for localised fat deposits rather than generalised adiposity. Patients with very high BMI are poor candidates.
- Skin laxity: Moderate-to-good skin elasticity is preferable. Significant pre-existing laxity may worsen after fat reduction; a frank conversation about this is part of appropriate consent.
- Realistic expectations: Patients expecting dramatic, rapid change are at high risk of dissatisfaction. The treatment produces gradual contouring, not transformation.
- Contraindications: Active infection at or near the treatment site, pregnancy or breastfeeding, severe systemic disease (including autoimmune conditions affecting wound healing), known hypersensitivity to any component, and active anticoagulant therapy (relative contraindication requiring clinical judgement).
Evidence-level note: The strongest RCT evidence supports the deoxycholic-acid class for submental use specifically. Extrapolating that evidence to other body areas or to different formulations requires clinical caution. The absence of head-to-head RCTs between Aqualyx-style microgel and prescription deoxycholic-acid formulations means practitioners are working with class-level and real-world evidence for most body-area applications.
How does cost shape choice and what are the legitimate supply channels?
Cost is a real factor in clinic procurement decisions, but it should never be the primary driver when regulatory compliance and patient safety are at stake.
Cost shape
Aqualyx-style CE-marked vials typically carry a lower per-vial cost than prescription deoxycholic-acid formulations. However, the higher session count often required for larger body areas means the total treatment cost to the patient may be comparable. Prescription formulations may cost more per vial but can achieve the submental result in fewer sessions. Present this to patients as a cost-per-outcome conversation, not a per-vial price comparison.
Legitimate supply channels
- Source only from licensed pharmacies or authorised distributors with a documented supply chain.
- Request batch numbers, lot certificates, and authorised distributor letters before accepting any order.
- Retain all invoices and batch records on file; these are essential for adverse event reporting and indemnity purposes.
- Never purchase from social media vendors, unverified online marketplaces, or suppliers who cannot provide pharmacy registration details.
Pro Tip: Check the MHRA’s list of registered pharmacies and authorised suppliers before placing any order for injectable aesthetic products. An authorised distributor letter from the manufacturer is a minimum standard, not an optional extra.
Training expectations
Practitioners offering injectable adipocytolysis should hold documented training from a recognised academy or manufacturer programme, covering injection anatomy, technique, complication recognition, and emergency management. For prescription deoxycholic-acid formulations, some manufacturers require completion of their own training programme before supply. Indemnity insurers increasingly require evidence of specific training for aesthetic injectable procedures; check your policy before adding a new treatment to your menu.
A practical checklist for choosing between agents
For qualified aesthetic professionals and well-informed patients working through shared decision-making, the following checklist converts the comparison into a clinical decision framework.
Clinician checklist
- Match agent to area: CE-marked microgel for larger or multiple body pockets; prescription deoxycholic-acid formulations for isolated, small submental deposits.
- Assess patient downtime tolerance: If the patient cannot accommodate 2–4 weeks of visible swelling, a microgel-based approach with its more gradual inflammatory profile is the more practical choice.
- Confirm supply chain: Can you source the chosen product through a licensed pharmacy with full batch traceability? If not, do not proceed.
- Confirm training: Do you hold documented training specific to the agent and area you plan to treat? If not, complete training before offering the treatment.
- Plan dosing and follow-up: Agree session count, interval, and assessment point before the first treatment. Build in a review appointment at 4–6 weeks post-final session.
- Document pre-treatment: Standardised photographs from multiple angles, signed consent covering the full complication profile, and a record of contraindication screening.
Patient questions for consent consultations
- How much swelling should I expect and for how long?
- How many sessions will I likely need, and how far apart?
- What results are realistic for my specific area and fat volume?
- What are the red flags I should contact the clinic about immediately?
- Who will manage any complications, and what is the escalation pathway?
- What aftercare do I need to follow to support recovery?
Documentation points
Pre- and post-treatment photographs at standardised angles, a consent form covering all material risks (including rare nerve injury for submental work), a follow-up schedule, and batch records for every vial used. These are not optional extras — they are the minimum standard for defensible practice.
What do the trials and regulator statements actually show?
For licensed practitioners who need to evaluate the strength of claims before incorporating a treatment into their practice, the evidence hierarchy matters.
Key trials and systematic reviews
Phase-3 trials for the deoxycholic-acid class in submental fat are the most methodologically robust evidence in this category. These randomised, placebo-controlled studies demonstrated statistically significant reduction in submental fat, with some multi-year follow-up data indicating that responders maintained meaningful improvement. This is class-level evidence for submental use; it does not automatically transfer to other body areas or to different formulations.
Systematic and narrative reviews of injectable adipocytolysis highlight the heterogeneity of the evidence base. Stronger RCT evidence exists for the prescription submental formulation; Aqualyx-style products are supported predominantly by observational data, post-market surveillance, and extensive real-world European use. The reviews consistently note that direct head-to-head RCTs between different formulations are limited.
| Evidence type | Deoxycholic-acid class (submental) | Aqualyx-style microgel |
|---|---|---|
| Randomised controlled trials | Phase-3 trials with placebo control | Limited; predominantly observational |
| Long-term follow-up data | Multi-year follow-up reported in responders | Post-market real-world data |
| Regulatory authorisation | FDA-authorised for submental use (US); prescription-only in UK | CE-marked; licensed pharmacy supply in UK/EU |
| Head-to-head RCTs vs other formulations | Not available | Not available |
Regulator statements
MHRA and professional body position: UK regulators have issued warnings about unlicensed cosmetic injectables, including fat-dissolving products, sold outside licensed pharmacy supply chains. The core concern is unknown formulation quality and the absence of traceability. CE marking and licensed pharmacy distribution are the minimum standards practitioners should require of any injectable product they use.
Evidence gaps
No published head-to-head RCT directly compares Aqualyx-style microgel with prescription deoxycholic-acid formulations. Practitioners should treat comparative claims — including those in this article — as informed clinical synthesis rather than RCT-level evidence. The strongest basis for choosing between agents remains the regulatory framework, the treatment area, and the patient’s clinical profile.
What is the verdict for UK practice by clinical scenario?
For qualified aesthetic professionals working within a UK regulatory framework, the decision between a CE-marked microgel and a prescription deoxycholic-acid formulation comes down to three scenarios.
- Favour CE-marked Aqualyx-style microgel when: the treatment area is larger than the submental region (abdomen, thighs, flanks, jowls), the patient has limited downtime tolerance, you are treating multiple areas in one session, or you need a product with a well-documented UK supply chain and established real-world safety data.
- Favour prescription deoxycholic-acid formulations when: the indication is a small, isolated submental fat deposit, the patient accepts a more pronounced inflammatory phase, you have completed the required prescribing and training requirements, and your supply chain is fully compliant with prescription-only medicine regulations.
- Avoid injectable adipocytolysis altogether when: the patient has active infection at the treatment site, is pregnant or breastfeeding, has significant skin laxity that fat reduction would worsen, holds unrealistic expectations that cannot be corrected through consultation, or when you cannot source the product through a verified, licensed supply chain.
Final clinical caution: Injectable adipocytolysis should only be offered within the remit of a practitioner’s documented training, prescribing authority, and governance framework. Offering treatments beyond your competency, or sourcing products outside licensed channels, exposes patients to avoidable harm and practitioners to serious professional and legal consequences. Governance is not optional — it is the foundation on which safe aesthetic practice is built.
An editorial perspective on sourcing and training decisions
The enquiries that reach qualified aesthetic professionals most often are not about which product works better in theory. They are about what to do when a supplier offers a product at a price that seems too good, or when a patient arrives having seen a treatment advertised on social media by someone with no visible credentials.
For qualified aesthetic professionals, the practical answer is always the same: the supply chain question comes before the product question. A CE-marked product through an authorised distributor with full batch traceability is a different clinical proposition from the same-sounding product sourced from an unverified online vendor — even if the label looks identical. The pitfalls seen most frequently in clinics are not about choosing the wrong formulation for the wrong area. They are about sourcing shortcuts that remove the traceability and quality assurance that make adverse event management possible.
The training question is equally consistent. Practitioners who have completed documented, anatomy-specific training for injectable adipocytolysis manage complications differently from those who have not. The marginal mandibular nerve is not forgiving of imprecise depth control, and a nodule that becomes a legal matter is almost always one where the consent form was thin and the follow-up plan was absent.
The comparison between a CE-marked microgel and a prescription deoxycholic-acid formulation is genuinely useful clinical knowledge. But it only matters if the practitioner asking the question has already answered the sourcing and training questions correctly.
Mirror Pharma supplies Aqualyx fat dissolve for licensed practitioners
Mirror Pharma is a compliant UK aesthetic supplier providing Aqualyx fat dissolve vials through verified, authorised channels to licensed practitioners and aesthetic clinics. Every order requires prescriber verification at checkout, and full batch traceability is maintained throughout the supply chain. Mirror Pharma’s catalogue also covers complementary body-contouring options, including body-contouring fillers for practitioners evaluating a broader treatment menu. All products are intended for use by trained, qualified professionals operating within their scope of practice and local regulatory requirements. Browse the Mirror Pharma shop to verify availability, confirm your prescriber status, and place a compliant order.
Sources
- PMC article (PMC10831194)
- Aqualyx vs. Lemon Bottle Fat Dissolving Injections – Riverbanks Clinic
- Aqualyx vs Lemon Bottle Fat Dissolving Injections – CoLaz
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
FAQ
What is the strongest fat-dissolving injectable available?
No single agent is universally “strongest” — the appropriate choice depends on the treatment area and patient profile. Prescription deoxycholic-acid formulations produce a faster, more aggressive adipocyte disruption suited to small submental deposits, while CE-marked Aqualyx-style microgel offers a more gradual effect better suited to larger body pockets.
Does Aqualyx permanently remove fat cells?
Adipocytes destroyed by Aqualyx-style treatment do not regenerate, so the reduction in fat-cell number is lasting. However, remaining fat cells in the treated area can still enlarge with significant weight gain, so results are durable rather than unconditional.
Is there a better alternative to prescription deoxycholic-acid formulations for body areas?
For larger body pockets such as the abdomen, thighs, and flanks, CE-marked Aqualyx-style microgel is generally the preferred option among licensed practitioners, offering a more established UK supply chain and a milder inflammatory profile suited to treating broader areas.
Will fat return after injectable adipocytolysis treatment?
Destroyed fat cells do not return, but the result depends on weight stability. Patients who gain significant weight after treatment may see the treated area expand again as remaining fat cells enlarge; practitioners should communicate this clearly during the consent process.